TempraMed Technologies Ltd.

As of June 30, 2026, TempraMed Technologies Ltd. carries a market capitalization of 46.61M, placing it among publicly traded companies globally. Its enterprise value stands at 48.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, TempraMed Technologies Ltd. has 79.01M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 16.13, and the price-to-book ratio stands at -11.16.

These figures are as of June 30, 2026. The EV/Sales ratio of 17.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 48.83M versus a market cap of 46.61M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TempraMed Technologies Ltd. maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -54.03, indicating conservative leverage, while an interest coverage ratio of -24.76 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -892.55, reflecting losses generated across the asset base. Inventory turnover of 2.82 indicates how many times TempraMed Technologies Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures are as of the close on October 7, 2026.

Over the twelve months ended June 30, 2026, TempraMed Technologies Ltd. generated 2.76M in revenue and converted that into -28.95M in net income, yielding earnings per share of -0.38. EBITDA reached -9.87M, while operating income came in at -9.96M.

As of June 30, 2026, TempraMed Technologies Ltd. holds 39,737.88 in cash and equivalents against 2.26M in total debt, resulting in a net debt position of 2.22M. Total book value stands at -4.18M, with working capital of -3.45M providing operational flexibility.

TempraMed Technologies Ltd. produced -6.53M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1,419.21 in capital expenditures, free cash flow totaled -6.53M - equivalent to -0.09 per share.

Over the twelve months ended June 30, 2026, TempraMed Technologies Ltd. posted a gross margin of 43.86, reflecting its pricing power and cost economics. The operating margin of -360.30 and net profit margin of -1,047.87 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.66: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.38, meaning TempraMed Technologies Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, TempraMed Technologies Ltd. has an Altman Z-Score of -57.68, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.